Skip to main content

Advertisement

SpringerLink
Log in

IL-6 −174G>C polymorphism and cancer risk: a meta-analysis involving 29,377 cases and 37,739 controls

  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

Interleukin-6 (IL-6) is a multifunctional cytokine involved in different physiologic and pathophysiologic processes and plays important roles in the etiology of cancer. The −174G>C polymorphism of the IL-6 gene influences IL-6 transcription and has been implicated in cancer risk. However, published data have been conflicting. To derive a more precise estimation of the relationship, a meta-analysis of 29,377 cancer cases and 37,739 controls from 50 published case–control studies was performed. Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated to assess the association between −174G>C polymorphism and cancer risk. Overall meta-analysis indicated that no association was found between −174G>C genotypes and cancer risk. However, the positive association was found in bladder cancer (OR = 4.33, 95% CI: 1.93–9.71 for CC vs. GC, OR = 2.81, 95% CI: 1.39–5.68 for CC vs. GG, and OR = 2.19, 95% CI: 1.32–3.64 for CC vs. GG/GC), and among Asians (OR = 2.08, 95% CI: 1.07–4.06 for CC vs. GG, and OR = 2.20, 95% CI: 1.02–4.74 for CC vs. GG/GC) and Africans (OR = 1.61, 95% CI: 1.07–2.42 for GC vs. GG). This meta-analysis showed the evidence that the −174G>C of the IL-6 gene was a low-penetrance susceptibility gene for bladder cancer. Further larger, perferably prospective studies are needed to confirm this relationship.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Abbreviations

OR:

Odds ratio

CI:

Confidence interval

IL-6:

Interleukin-6

References

  1. Shacter E, Weitzman SA (2002) Chronic inflammation and cancer. Oncology (Williston Park), 16, 217-226, 229; Discussion 230–232

    Google Scholar 

  2. Samsami Dehaghani A, Shahriary K, Kashef MA, Naeimi S, Fattahi MJ, Mojtahedi Z, Ghaderi A (2009) Interleukin-18 gene promoter and serum level in women with ovarian cancer. Mol Biol Rep 36:2393–2397

    Article  PubMed  CAS  Google Scholar 

  3. Zhang L, Du C, Guo X, Yuan L, Niu W, Yu W, Er L, Wang S (2010) Interleukin-8–251A/T polymorphism and Helicobacter pylori infection influence risk for the development of gastric cardiac adenocarcinoma in a high-incidence area of China. Mol Biol Rep 37(8):3983–3989. doi:10.1007/s11033-010-0057-7

    Article  PubMed  CAS  Google Scholar 

  4. Jackson JR, Seed MP, Kircher CH, Willoughby DA, Winkler JD (1997) The codependence of angiogenesis and chronic inflammation. Faseb J 11:457–465

    PubMed  CAS  Google Scholar 

  5. Phoa N, Epe B (2002) Influence of nitric oxide on the generation and repair of oxidative DNA damage in mammalian cells. Carcinogenesis 23:469–475

    Article  PubMed  CAS  Google Scholar 

  6. Moore MA (2002) Cytokine and chemokine networks influencing stem cell proliferation, differentiation, and marrow homing. J Cell Biochem Suppl 38:29–38

    Article  PubMed  Google Scholar 

  7. Diehl S, Rincon M (2002) The two faces of IL-6 on Th1/Th2 differentiation. Mol Immunol 39:531–536

    Article  PubMed  CAS  Google Scholar 

  8. Asschert JG, Vellenga E, Ruiters MH, de Vries EG (1999) Regulation of spontaneous and TNF/IFN-induced IL-6 expression in two human ovarian-carcinoma cell lines. Int J Cancer 82:244–249

    Article  PubMed  CAS  Google Scholar 

  9. Takeda K, Fujii N, Nitta Y, Sakihara H, Nakayama K, Rikiishi H, Kumagai K (1991) Murine tumor cells metastasizing selectively in the liver: ability to produce hepatocyte-activating cytokines interleukin-1 and/or -6. Jpn J Cancer Res 82:1299–1308

    PubMed  CAS  Google Scholar 

  10. DeMichele A, Martin AM, Mick R, Gor P, Wray L, Klein-Cabral M, Athanasiadis G, Colligan T, Stadtmauer E, Weber B (2003) Interleukin-6–174G>C polymorphism is associated with improved outcome in high-risk breast cancer. Cancer Res 63:8051–8056

    PubMed  CAS  Google Scholar 

  11. Ray A, LaForge KS, Sehgal PB (1990) On the mechanism for efficient repression of the interleukin-6 promoter by glucocorticoids: enhancer, TATA box, and RNA start site (Inr motif) occlusion. Mol Cell Biol 10:5736–5746

    PubMed  CAS  Google Scholar 

  12. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P (1998) The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 102:1369–1376

    Article  PubMed  CAS  Google Scholar 

  13. Litovkin KV, Domenyuk VP, Bubnov VV, Zaporozhan VN (2007) Interleukin-6–174G/C polymorphism in breast cancer and uterine leiomyoma patients: a population-based case control study. Exp Oncol 29:295–298

    PubMed  CAS  Google Scholar 

  14. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748

    PubMed  CAS  Google Scholar 

  15. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188

    Article  PubMed  CAS  Google Scholar 

  16. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. Bmj 315:629–634

    PubMed  CAS  Google Scholar 

  17. Duch CR, Figueiredo MS, Ribas C, Almeida MS, Colleoni GW, Bordin JO (2007) Analysis of polymorphism at site -174 G/C of interleukin-6 promoter region in multiple myeloma. Braz J Med Biol Res 40:265–267

    Article  PubMed  CAS  Google Scholar 

  18. Landi S, Moreno V, Gioia-Patricola L, Guino E, Navarro M, de Oca J, Capella G, Canzian F (2003) Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Res 63:3560–3566

    PubMed  CAS  Google Scholar 

  19. Smith KC, Bateman AC, Fussell HM, Howell WM (2004) Cytokine gene polymorphisms and breast cancer susceptibility and prognosis. Eur J Immunogenet 31:167–173

    Article  PubMed  CAS  Google Scholar 

  20. Talar-Wojnarowska R, Gasiorowska A, Smolarz B, Romanowicz-Makowska H, Kulig A, Malecka-Panas E (2009) Clinical significance of interleukin-6 (IL-6) gene polymorphism and IL-6 serum level in pancreatic adenocarcinoma and chronic pancreatitis. Dig Dis Sci 54:683–689

    Article  PubMed  CAS  Google Scholar 

  21. Howell WM, Turner SJ, Theaker JM, Bateman AC (2003) Cytokine gene single nucleotide polymorphisms and susceptibility to and prognosis in cutaneous malignant melanoma. Eur J Immunogenet 30:409–414

    Article  PubMed  CAS  Google Scholar 

  22. Cordano P, Lake A, Shield L, Taylor GM, Alexander FE, Taylor PR, White J, Jarrett RF (2005) Effect of IL-6 promoter polymorphism on incidence and outcome in Hodgkin’s lymphoma. Br J Haematol 128:493–495

    Article  PubMed  CAS  Google Scholar 

  23. Snoussi K, Strosberg AD, Bouaouina N, Ben Ahmed S, Chouchane L (2005) Genetic variation in pro-inflammatory cytokines (interleukin-1beta, interleukin-1alpha and interleukin-6) associated with the aggressive forms, survival, and relapse prediction of breast carcinoma. Eur Cytokine Netw 16:253–260

    PubMed  CAS  Google Scholar 

  24. Vasku JA, Vasku A, Goldbergova M, Vasku V (2004) Heterozygote AG variant of -596 A/G IL-6 gene polymorphism is a marker for cutaneous T-cell lymphoma (CTCL). Clin Immunol 113:256–260

    Article  PubMed  CAS  Google Scholar 

  25. Deans C, Rose-Zerilli M, Wigmore S, Ross J, Howell M, Jackson A, Grimble R, Fearon K (2007) Host cytokine genotype is related to adverse prognosis and systemic inflammation in gastro-oesophageal cancer. Ann Surg Oncol 14:329–339

    Article  PubMed  Google Scholar 

  26. Berkovic MC, Jokic M, Marout J, Radosevic S, Zjacic-Rotkvic V, Kapitanovic S (2007) IL-6–174 C/G polymorphism in the gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Exp Mol Pathol 83:474–479

    Article  PubMed  CAS  Google Scholar 

  27. Mazur G, Bogunia-Kubik K, Wrobel T, Karabon L, Polak M, Kuliczkowski K, Lange A (2005) IL-6 and IL-10 promoter gene polymorphisms do not associate with the susceptibility for multiple myeloma. Immunol Lett 96:241–246

    Article  PubMed  CAS  Google Scholar 

  28. Nearman ZP, Wlodarski M, Jankowska AM, Howe E, Narvaez Y, Ball E, Maciejewski JP (2007) Immunogenetic factors determining the evolution of T-cell large granular lymphocyte leukaemia and associated cytopenias. Br J Haematol 136:237–248

    Article  PubMed  CAS  Google Scholar 

  29. Hefler LA, Grimm C, Lantzsch T, Lampe D, Leodolter S, Koelbl H, Heinze G, Reinthaller A, Tong-Cacsire D, Tempfer C, Zeillinger R (2005) Interleukin-1 and interleukin-6 gene polymorphisms and the risk of breast cancer in caucasian women. Clin Cancer Res 11:5718–5721

    Article  PubMed  CAS  Google Scholar 

  30. Martinez-Escribano JA, Moya-Quiles MR, Muro M, Montes-Ares O, Hernandez-Caselles T, Frias JF, Alvarez-Lopez MR (2002) Interleukin-10, interleukin-6 and interferon-gamma gene polymorphisms in melanoma patients. Melanoma Res 12:465–469

    Article  PubMed  CAS  Google Scholar 

  31. Gonzalez-Zuloeta Ladd AM, Arias Vasquez A, Witteman J, Uitterlinden AG, Coebergh JW, Hofman A, Stricker BH, van Duijn CM (2006) Interleukin 6 G-174 C polymorphism and breast cancer risk. Eur J Epidemiol 21:373–376

    Article  PubMed  CAS  Google Scholar 

  32. Zheng C, Huang DR, Bergenbrant S, Sundblad A, Osterborg A, Bjorkholm M, Holm G, Yi Q (2000) Interleukin 6, tumour necrosis factor alpha, interleukin 1beta and interleukin 1 receptor antagonist promoter or coding gene polymorphisms in multiple myeloma. Br J Haematol 109:39–45

    Article  PubMed  CAS  Google Scholar 

  33. Cherel M, Campion L, Bezieau S, Campone M, Charrier J, Gaschet J, Ricolleau G, Gouraud W, Charbonnel C, Jezequel P (2009) Molecular screening of interleukin-6 gene promoter and influence of -174G/C polymorphism on breast cancer. Cytokine 47(3):214–223

    Article  PubMed  CAS  Google Scholar 

  34. Vasku A, Vokurka J, Bienertova-Vasku J (2009) Obesity-related genes variability in Czech patients with sporadic colorectal cancer: preliminary results. Int J Colorectal Dis 24:289–294

    Article  PubMed  Google Scholar 

  35. Gonullu G, Basturk B, Evrensel T, Oral B, Gozkaman A, Manavoglu O (2007) Association of breast cancer and cytokine gene polymorphism in Turkish women. Saudi Med J 28:1728–1733

    PubMed  Google Scholar 

  36. Kamangar F, Abnet CC, Hutchinson AA, Newschaffer CJ, Helzlsouer K, Shugart YY, Pietinen P, Dawsey SM, Albanes D, Virtamo J, Taylor PR (2006) Polymorphisms in inflammation-related genes and risk of gastric cancer (Finland). Cancer Causes Control 17:117–125

    Article  PubMed  Google Scholar 

  37. Seifart C, Plagens A, Dempfle A, Clostermann U, Vogelmeier C, von Wichert P, Seifart U (2005) TNF-alpha, TNF-beta, IL-6, and IL-10 polymorphisms in patients with lung cancer. Dis Markers 21:157–165

    PubMed  CAS  Google Scholar 

  38. Zhang Z, Liu W, Jia X, Gao Y, Hemminki K, Lindholm B (2004) Use of pyrosequencing to detect clinically relevant polymorphisms of genes in basal cell carcinoma. Clin Chim Acta 342:137–143

    Article  PubMed  CAS  Google Scholar 

  39. Ahirwar D, Kesarwani P, Manchanda PK, Mandhani A, Mittal RD (2008) Anti- and proinflammatory cytokine gene polymorphism and genetic predisposition: association with smoking, tumor stage and grade, and bacillus Calmette-Guerin immunotherapy in bladder cancer. Cancer Genet Cytogenet 184:1–8

    Article  PubMed  CAS  Google Scholar 

  40. Campa D, Zienolddiny S, Maggini V, Skaug V, Haugen A, Canzian F (2004) Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis 25:229–235

    Article  PubMed  CAS  Google Scholar 

  41. Slattery ML, Wolff RK, Herrick JS, Caan BJ, Potter JD (2007) IL6 genotypes and colon and rectal cancer. Cancer Causes Control 18:1095–1105

    Article  PubMed  Google Scholar 

  42. Rothman N, Skibola CF, Wang SS, Morgan G, Lan Q, Smith MT, Spinelli JJ, Willett E, De Sanjose S, Cocco P, Berndt SI, Brennan P, Brooks-Wilson A, Wacholder S, Becker N, Hartge P, Zheng T, Roman E, Holly EA, Boffetta P, Armstrong B, Cozen W, Linet M, Bosch FX, Ennas MG, Holford TR, Gallagher RP, Rollinson S, Bracci PM, Cerhan JR, Whitby D, Moore PS, Leaderer B, Lai A, Spink C, Davis S, Bosch R, Scarpa A, Zhang Y, Severson RK, Yeager M, Chanock S, Nieters A (2006) Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol 7:27–38

    Article  PubMed  CAS  Google Scholar 

  43. Balasubramanian SP, Azmy IA, Higham SE, Wilson AG, Cross SS, Cox A, Brown NJ, Reed MW (2006) Interleukin gene polymorphisms and breast cancer: a case control study and systematic literature review. BMC Cancer 6:188

    Article  PubMed  CAS  Google Scholar 

  44. Ennas MG, Moore PS, Zucca M, Angelucci E, Cabras MG, Melis M, Gabbas A, Serpe R, Madeddu C, Scarpa A, Cocco P (2008) Interleukin-1B (IL1B) and interleukin-6 (IL6) gene polymorphisms are associated with risk of chronic lymphocytic leukaemia. Hematol Oncol 26:98–103

    Article  PubMed  CAS  Google Scholar 

  45. Gunter MJ, Canzian F, Landi S, Chanock SJ, Sinha R, Rothman N (2006) Inflammation-related gene polymorphisms and colorectal adenoma. Cancer Epidemiol Biomarkers Prev 15:1126–1131

    Article  PubMed  CAS  Google Scholar 

  46. Vogel U, Christensen J, Nexo BA, Wallin H, Friis S, Tjonneland A (2007) Peroxisome proliferator-activated [corrected] receptor-gamma2 [corrected] Pro12Ala, interaction with alcohol intake and NSAID use, in relation to risk of breast cancer in a prospective study of Danes. Carcinogenesis 28:427–434

    Article  PubMed  CAS  Google Scholar 

  47. Vogel U, Christensen J, Wallin H, Friis S, Nexo BA, Raaschou-Nielsen O, Overvad K, Tjonneland A (2008) Polymorphisms in genes involved in the inflammatory response and interaction with NSAID use or smoking in relation to lung cancer risk in a prospective study. Mutat Res 639:89–100

    PubMed  CAS  Google Scholar 

  48. Vogel U, Christensen J, Wallin H, Friis S, Nexo BA, Tjonneland A (2007) Polymorphisms in COX-2, NSAID use and risk of basal cell carcinoma in a prospective study of Danes. Mutat Res 617:138–146

    Article  PubMed  CAS  Google Scholar 

  49. Wilkening S, Tavelin B, Canzian F, Enquist K, Palmqvist R, Altieri A, Hallmans G, Hemminki K, Lenner P, Forsti A (2008) Interleukin promoter polymorphisms and prognosis in colorectal cancer. Carcinogenesis 29:1202–1206

    Article  PubMed  CAS  Google Scholar 

  50. Lan Q, Zheng T, Rothman N, Zhang Y, Wang SS, Shen M, Berndt SI, Zahm SH, Holford TR, Leaderer B, Yeager M, Welch R, Boyle P, Zhang B, Zou K, Zhu Y, Chanock S (2006) Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood 107:4101–4108

    Article  PubMed  CAS  Google Scholar 

  51. Gatti LL, Burbano RR, Zambaldi-Tunes M, de-Labio RW, de Assumpcao PP, de Arruda Cardoso-Smith M, Marques-Payao SL (2007) Interleukin-6 polymorphisms, Helicobacter pylori infection in adult Brazilian patients with chronic gastritis and gastric adenocarcinoma. Arch Med Res 38:551–555

    Article  PubMed  Google Scholar 

  52. Aladzsity I, Kovacs M, Semsei A, Falus A, Szilagyi A, Karadi I, Varga G, Fust G, Varkonyi J (2009) Comparative analysis of IL6 promoter and receptor polymorphisms in myelodysplasia and multiple myeloma. Leuk Res 33:1570–1573

    Article  PubMed  CAS  Google Scholar 

  53. Andrie E, Michos A, Kalampoki V, Pourtsidis A, Moschovi M, Polychronopoulou S, Athanasiadou-Piperopoulou F, Kalmanti M, Hatzakis A, Paraskevis D, Nieters A, Petridou ET (2009) Genetic variants in immunoregulatory genes and risk for childhood lymphomas. Eur J Haematol 83:334–342

    Article  PubMed  CAS  Google Scholar 

  54. Kesarwani P, Ahirwar DK, Mandhani A, Mittal RD (2008) Association between -174 G/C promoter polymorphism of the interleukin-6 gene and progression of prostate cancer in North Indian population. DNA Cell Biol 27:505–510

    Article  PubMed  CAS  Google Scholar 

  55. Slattery ML, Wolff RK, Curtin K, Fitzpatrick F, Herrick J, Potter JD, Caan BJ, Samowitz WS (2009) Colon tumor mutations and epigenetic changes associated with genetic polymorphism: insight into disease pathways. Mutat Res 660:12–21

    Article  PubMed  CAS  Google Scholar 

  56. Festa F, Kumar R, Sanyal S, Unden B, Nordfors L, Lindholm B, Snellman E, Schalling M, Forsti A, Hemminki K (2005) Basal cell carcinoma and variants in genes coding for immune response, DNA repair, folate and iron metabolism. Mutat Res 574:105–111

    Article  PubMed  CAS  Google Scholar 

  57. Gangwar R, Mittal B, Mittal RD (2009) Association of interleukin-6–174G>C promoter polymorphism with risk of cervical cancer. Int J Biol Markers 24:11–16

    PubMed  CAS  Google Scholar 

  58. Leibovici D, Grossman HB, Dinney CP, Millikan RE, Lerner S, Wang Y, Gu J, Dong Q, Wu X (2005) Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. J Clin Oncol 23:5746–5756

    Article  PubMed  CAS  Google Scholar 

  59. Liang XS, Caporaso N, McMaster ML, Ng D, Landgren O, Yeager M, Chanock S, Goldin LR (2009) Common genetic variants in candidate genes and risk of familial lymphoid malignancies. Br J Haematol 146:418–423

    Article  PubMed  CAS  Google Scholar 

  60. Ozgen AG, Karadeniz M, Erdogan M, Berdeli A, Saygili F, Yilmaz C (2009) The (-174) G/C polymorphism in the interleukin-6 gene is associated with risk of papillary thyroid carcinoma in Turkish patients. J Endocrinol Invest 32:491–494

    PubMed  CAS  Google Scholar 

  61. Slattery ML, Curtin K, Baumgartner R, Sweeney C, Byers T, Giuliano AR, Baumgartner KB, Wolff RR (2007) IL6, aspirin, nonsteroidal anti-inflammatory drugs, and breast cancer risk in women living in the southwestern United States. Cancer Epidemiol Biomarkers Prev 16:747–755

    Article  PubMed  CAS  Google Scholar 

  62. Slattery ML, Curtin K, Sweeney C, Wolff RK, Baumgartner RN, Baumgartner KB, Giuliano AR, Byers T (2008) Modifying effects of IL-6 polymorphisms on body size-associated breast cancer risk. Obesity (Silver Spring) 16:339–347

    Article  CAS  Google Scholar 

  63. Cozen W, Gebregziabher M, Conti DV, Van Den Berg DJ, Coetzee GA, Wang SS, Rothman N, Bernstein L, Hartge P, Morhbacher A, Coetzee SG, Salam MT, Wang W, Zadnick J, Ingles SA (2006) Interleukin-6-related genotypes, body mass index, and risk of multiple myeloma and plasmacytoma. Cancer Epidemiol Biomarkers Prev 15:2285–2291

    Article  PubMed  CAS  Google Scholar 

  64. Vairaktaris E, Yiannopoulos A, Vylliotis A, Yapijakis C, Derka S, Vassiliou S, Nkenke E, Serefoglou Z, Ragos V, Tsigris C, Vorris E, Critselis E, Avgoustidis D, Neukam FW, Patsouris E (2006) Strong association of interleukin-6–174 > C promoter polymorphism with increased risk of oral cancer. Int J Biol Markers 21:246–250

    PubMed  CAS  Google Scholar 

  65. Skerrett DL, Moore EM, Bernstein DS, Vahdat L (2005) Cytokine genotype polymorphisms in breast carcinoma: associations of TGF-beta1 with relapse. Cancer Invest 23:208–214

    Article  PubMed  CAS  Google Scholar 

  66. Dossus L, Kaaks R, Canzian F, Albanes D, Berndt SI, Boeing H, Buring J, Chanock SJ, Clavel-Chapelon F, Feigelson HS, Gaziano JM, Giovannucci E, Gonzalez C, Haiman CA, Hallmans G, Hankinson SE, Hayes RB, Henderson BE, Hoover RN, Hunter DJ, Khaw KT, Kolonel LN, Kraft P, Ma J, Le Marchand L, Lund E, Peeters PH, Stampfer M, Stram DO, Thomas G, Thun MJ, Tjonneland A, Trichopoulos D, Tumino R, Riboli E, Virtamo J, Weinstein SJ, Yeager M, Ziegler RG, Cox DG (2010) PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3). Carcinogenesis 31:455–461

    Article  PubMed  CAS  Google Scholar 

  67. Falleti E, Fabris C, Toniutto P, Fontanini E, Cussigh A, Bitetto D, Fumolo E, Fornasiere E, Bragagnini W, Pinato DJ, Minisini R, Pirisi M (2009) Interleukin-6 polymorphisms and gender: relationship with the occurrence of hepatocellular carcinoma in patients with end-stage liver disease. Oncology 77:304–313

    Article  PubMed  CAS  Google Scholar 

  68. Cacev T, Jokic M, Loncar B, Krizanac S, Kapitanovic S (2010) Interleukin-6–174 G/C polymorphism is not associated with IL-6 expression and susceptibility to sporadic colon cancer. DNA Cell Biol 29:177–182

    Article  PubMed  CAS  Google Scholar 

  69. Tsilidis KK, Helzlsouer KJ, Smith MW, Grinberg V, Hoffman-Bolton J, Clipp SL, Visvanathan K, Platz EA (2009) Association of common polymorphisms in IL10, and in other genes related to inflammatory response and obesity with colorectal cancer. Cancer Causes Control 20:1739–1751

    Article  PubMed  Google Scholar 

  70. Tan D, Wu X, Hou M, Lee SO, Lou W, Wang J, Janarthan B, Nallapareddy S, Trump DL, Gao AC (2005) Interleukin-6 polymorphism is associated with more aggressive prostate cancer. J Urol 174:753–756

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported by the Foundation of Key Medical Department of Jiangsu Province—Department of Urology of Jiangsu Province Hospital (XK17 200904), National Natural Science Foundation of China (NO. 30872575), Foundation of Key Medical Department of Jiangsu Province—Department of General Surgery of Jiangsu Province Hospital and National Eleventh-Five Science and Technology Support Program of China (No. 2006BAI03B12).

Author information

Authors and Affiliations

  1. Department of Urology, Laboratory of Reproductive Medicine, First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, 210029, Nanjing, China

    Bin Xu, Xiao-Bing Niu, Zi-Dun Wang, Wei Cheng, Yuan-Yuan Mi, Zhi-Chao Min, Jun Tao, Peng-Chao Li, Wei Zhang, Hong-Fei Wu, Zeng-Jun Wang, Li-Xin Hua & Ning-Han Feng

  2. Department of Molecular and Genetic Toxicology, Cancer Center of Nanjing Medical University, 140 Hanzhong Road, 210029, Nanjing, China

    Bin Xu, Na Tong & Zheng-Dong Zhang

  3. Laboratory of Reproductive Medicine, Institute of Toxicology, Nanjing Medical University, 210029, Nanjing, China

    Xin-Ru Wang

Authors
  1. Bin Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiao-Bing Niu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zi-Dun Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wei Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Na Tong
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yuan-Yuan Mi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Zhi-Chao Min
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jun Tao
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Peng-Chao Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Wei Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Hong-Fei Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Zheng-Dong Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Zeng-Jun Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Li-Xin Hua
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Ning-Han Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Xin-Ru Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Zeng-Jun Wang or Li-Xin Hua.

Additional information

The authors Bin Xu, Xiao-Bing Niu, and Zi-Dun Wang contributed equally to this work.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOC 147 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Xu, B., Niu, XB., Wang, ZD. et al. IL-6 −174G>C polymorphism and cancer risk: a meta-analysis involving 29,377 cases and 37,739 controls. Mol Biol Rep 38, 2589–2596 (2011). https://doi.org/10.1007/s11033-010-0399-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-010-0399-1

Keywords

Search

Navigation